pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › NVO

NVO PDUFA Date: Sogroya (somapacitan)

FDA decision (PDUFA) target 2026-06-30 · Novo Nordisk A/S · Noonan syndrome (NS)

NVO run-up into the PDUFA (last ~120 days)

$49.23$35.29
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-06-30
Drug / candidateSogroya (somapacitan)
IndicationNoonan syndrome (NS)
CompanyNovo Nordisk A/S
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.gov—

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the NVO PDUFA date?
The FDA PDUFA target date for NVO (Novo Nordisk A/S) is 2026-06-30 for Sogroya (somapacitan). Dates are company/FDA-sourced and can slip — verify against primary filings.
What is NVO's drug Sogroya (somapacitan)?
Sogroya (somapacitan) is Novo Nordisk A/S's candidate under FDA review for Noonan syndrome (NS).
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.